Moore Jonathan M, Bell Eric L, Hughes Robert O, Garfield Alastair S
Rectify Pharmaceuticals, Cambridge, MA, USA.
Rectify Pharmaceuticals, Cambridge, MA, USA.
Trends Mol Med. 2023 Feb;29(2):152-172. doi: 10.1016/j.molmed.2022.11.001. Epub 2022 Dec 8.
Adenosine triphosphate (ATP)-binding cassette (ABC) transporters are a 48-member superfamily of membrane proteins that actively transport a variety of biological substrates across lipid membranes. Their functional diversity defines an expansive involvement in myriad aspects of human biology. At least 21 ABC transporters underlie rare monogenic disorders, with even more implicated in the predisposition to and symptomology of common and complex diseases. Such broad (patho)physiological relevance places this class of proteins at the intersection of disease causation and therapeutic potential, underlining them as promising targets for drug discovery, as exemplified by the transformative CFTR (ABCC7) modulator therapies for cystic fibrosis. This review will explore the growing relevance of ABC transporters to human disease and their potential as small-molecule drug targets.
三磷酸腺苷(ATP)结合盒(ABC)转运蛋白是一个由48个成员组成的膜蛋白超家族,可主动将多种生物底物转运穿过脂质膜。它们的功能多样性决定了其在人类生物学的众多方面有着广泛的参与。至少21种ABC转运蛋白是罕见单基因疾病的基础,甚至更多的ABC转运蛋白与常见和复杂疾病的易感性及症状有关。这种广泛的(病理)生理相关性使这类蛋白质处于疾病病因和治疗潜力的交叉点,突出了它们作为药物发现的有前景的靶点,囊性纤维化的变革性CFTR(ABCC7)调节剂疗法就是例证。本综述将探讨ABC转运蛋白与人类疾病日益增长的相关性及其作为小分子药物靶点的潜力。
Trends Mol Med. 2023-2
Biochem Pharmacol. 2017-7-15
Pflugers Arch. 2001
Biochim Biophys Acta. 2009-7
Cold Spring Harb Perspect Med. 2013-1-1
J Mol Neurosci. 2025-5-14